Disease · MONDO_0005453
congenital heart disease
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. congenital heart disease. Diseases, record MONDO_0005453. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005453
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Abnormal heart morphology, Abnormality of cardiac morphology, Abnormality of the heart, Abnormally shaped heart, CHD, Cardiac abnormality, Cardiac anomalies, Cardiac anomaly, Heart defect, congenital anomaly of heart, congenital heart defect, congenital heart defects
- Open Targets
Drugs37
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BOSENTAN | CHEMBL957 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| LIOTHYRONINE SODIUM | CHEMBL1201119 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SACUBITRIL | CHEMBL3137301 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VALSARTAN | CHEMBL1069 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOPAMINE | CHEMBL59 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPTACOG ALFA (ACTIVATED) | CHEMBL2108334 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NOREPINEPHRINE | CHEMBL1437 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 37
See all 37 drugsTargets67
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2560 | Drugs and targets |
1 to 10 of 67
See all 67 targetsTrials37
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03229538 | STeroids to REduce Systemic Inflammation After Infant Heart Surgery | Phase 3 | 1,263 | 2023-05-10 | Congenital Heart Disease in Children, Inflammatory Response | METHYLPREDNISOLONE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02320669 | Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass | Phase 3 | 220 | 2024-04-09 | Congenital Heart Defects | LIOTHYRONINE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03882788 | The Effect of Anesthesia on Neurodevelopmental Outcome (NDO) | Not applicable | 153 | 2022-05-09 | Anesthesia; Adverse Effect, Congenital Heart Disease, Neurodevelopmental Disorders | FENTANYL, ISOFLURANE | Its record names the disease | ClinicalTrials.gov |
| NCT02133573 | Randomized Trial of Maternal Progesterone Therapy | Phase 2 | 102 | 2023-02-28 | Congenital Heart Disease, Periventricular Leucomalacia, Brain Development, Cardiac Surgery, Neurodevelopmental Disability, Fetal Neuroprotection | PROGESTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT00620945 | Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass | Not applicable | 87 | 2017-11-20 | Congenital Heart Surgery, Cardiopulmonary Bypass | PHENOXYBENZAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00480740 | The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease | Phase 3 | 41 | 2015-06-26 | Cardiac Transplant, Patent Ductus Arterious, Atrial Septal Defect, Bidirectional Cavopulmonary Anastomosis | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT03417999 | Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease | Phase 1 | 28 | 2024-03-22 | Dexmedetomidine, Congenital Heart Disease | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00848250 | Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children | Not applicable | 21 | 2017-07-26 | Congenital Heart Disease | ANGIOTENSIN | Its record names the disease | ClinicalTrials.gov |
| NCT00590018 | Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease | Phase 2 | 18 | 2016-05-26 | Cardiac Output, Low | HYDROCORTISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00281671 | Nesiritide Use Following Cardiac Surgery in Infants | Phase 1/2 | 9 | 2020-08-27 | Heart Defects, Congenital, Cardiopulmonary Bypass | NESIRITIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 37
See all 37 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Prolonged Mechanical Ventilation (Greater Than 7 Days) | 41 of 599 | 51 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Post-operative Low Cardiac Output Syndrome | 31 of 599 | 37 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Mortality, Including In-hospital Mortality or Mortality After Hospital Discharge But Within 30 Days of the Last Dose of Study Drug | 12 of 599 | 17 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Death or Major Complication as Defined by an Outcome in One of the 7 Highest Global Ranking Categories | 103 of 599 | 122 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With Any Other Post-operative Complications From the Start of Study Drug Administration Until Hospital Discharge. | 237 of 599 | 264 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: Number of Participants With a Post-operative Length of Stay Greater Than 90 Days | 18 of 599 | 29 of 601 | 1,200 | NCT03229538 | Trial comparisons |
Methylprednisolone Arm vs Placebo Arm: Number of Participants With Occurrence of Any One or More of the Following STS-CHSD-defined Major Post-operative Infectious Complications: Postprocedural Infective Endocarditis, Pneumonia, Sepsis, Deep Wound Infection, Mediastinitis. | 31 of 599 | 24 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: deaths from any cause | 12 of 599 | 17 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Methylprednisolone Arm vs Placebo Arm: serious adverse events | 2 of 599 | 0 of 601 | 1,200 | NCT03229538 | Trial comparisons |
| Triostat vs Placebo: deaths from any cause | 6 of 110 | 3 of 110 | 220 | NCT02320669 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials36
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005453
GET https://conductscience.org/api/diseases/v1/MONDO_0005453/drugs?page=2